Derek DiRocco - Nov 14, 2022 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role: Director
Signature: /s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Stock symbol: ACRV
Transactions as of: Nov 14, 2022
Transactions value $: $0
Form type: 4
Date filed: 11/16/2022, 08:05 PM
Previous filing: Nov 9, 2022
Next filing: Feb 13, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRV	Stock Option (Right to Buy)	Award	$0	+35.2K		$0.00	35.2K	Nov 14, 2022	Common Stock	35.2K	$12.50	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to the option shall vest in 36 equal monthly installments starting on October 12, 2022 ("Vesting Commencement Date"), such that all shares are fully vested on the third anniversary of the Vesting Commencement Date, in each case subject to the Reporting Person's continuous service through each such vesting date.
F2	Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.

Content

The shares subject to the option shall vest in 36 equal monthly installments starting on October 12, 2022 ("Vesting Commencement Date"), such that all shares are fully vested on the third anniversary of the Vesting Commencement Date, in each case subject to the Reporting Person's continuous service through each such vesting date.

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.